Integration of home fortification with iron and intermittent preventive treatment against malaria: a randomised trial in Kenyan preschool children
|ING Staff:||Hans Verhoef, Emily Teshome, Andrew Prentice|
There are concerns about the safety of daily home fortification in malaria-endemic areas with iron at the dose (12.5 mg as ferrous salts) that has been recommended by the World Health Organization for children. Conversely, Plasmodium infection may reduce the efficacy of iron interventions. Integration of iron interventions with malaria control is likely to be safer and more efficacious than interventions with iron alone. The development of such integrated strategies requires knowledge of the formulation and dosage of fortificant iron to be used (home fortification with 3 mg iron as NaFeEDTA may be similarly or more effective to that obtained with 12.5 mg iron as ferrous salts) and of the frequency in which antimalarial drugs, coupled with iron interventions, should be administered. In the present randomised controlled non-inferiority trial, children will be protected against malaria by a single therapeutic course of dihydroartemisinin-piperaquine, with the aim to compare the haematological response to daily home fortification for 30 days with 3mg iron as NaFeEDTA or 12.5 mg iron as encapsulated ferrous fumarate.